Analytical Validation and Application of a Targeted Next-Generation Sequencing Mutation-Detection Assay for Use in Treatment Assignment in the NCI-MPACT.

Slides:

Advertisements

Similar presentations

Martina I. Lefterova, Peidong Shen, Justin I

Advertisements

Molecular Analysis of the Breast Cancer Genes BRCA1 and BRCA2 Using Amplicon- Based Massive Parallel Pyrosequencing Geneviève Michils, Silke Hollants,

Ane Y. Schmidt, Thomas v. O. Hansen, Lise B

Comparison of Clinical Targeted Next-Generation Sequence Data from Formalin-Fixed and Fresh-Frozen Tissue Specimens David H. Spencer, Jennifer K. Sehn,

Development of a Next-Generation Sequencing Method for BRCA Mutation Screening Maurice Chan, Shen Mo Ji, Zhen Xuan Yeo, Linda Gan, Eric Yap, Yoon Sim.

A Targeted High-Throughput Next-Generation Sequencing Panel for Clinical Screening of Mutations, Gene Amplifications, and Fusions in Solid Tumors Rajyalakshmi.

Assessing Copy Number Alterations in Targeted, Amplicon-Based Next-Generation Sequencing Data Catherine Grasso, Timothy Butler, Katherine Rhodes, Michael.

Martina I. Lefterova, Peidong Shen, Justin I

Haley J. Abel, Hussam Al-Kateb, Catherine E. Cottrell, Andrew J

Single-Color Digital PCR Provides High-Performance Detection of Cancer Mutations from Circulating DNA Christina Wood-Bouwens, Billy T. Lau, Christine.

Comprehensive Screening of Gene Copy Number Aberrations in Formalin-Fixed, Paraffin-Embedded Solid Tumors Using Molecular Inversion Probe–Based Single-

A Method to Evaluate the Quality of Clinical Gene-Panel Sequencing Data for Single- Nucleotide Variant Detection Chung Lee, Joon S. Bae, Gyu H. Ryu, Nayoung.

Validation of a Next-Generation Sequencing Pipeline for the Molecular Diagnosis of Multiple Inherited Cancer Predisposing Syndromes Paula Paulo, Pedro.

Methodologic Considerations in the Application of Next-Generation Sequencing of Human TRB Repertoires for Clinical Use Liwen Xu, Xiaoqing You, PingPing.

Performance of Common Analysis Methods for Detecting Low-Frequency Single Nucleotide Variants in Targeted Next-Generation Sequence Data David H. Spencer,

Suppression of Wild-Type Amplification by Selectivity Enhancing Agents in PCR Assays that Utilize SuperSelective Primers for the Detection of Rare Somatic.

Targeted, High-Depth, Next-Generation Sequencing of Cancer Genes in Formalin- Fixed, Paraffin-Embedded and Fine-Needle Aspiration Tumor Specimens Andrew.

Robustness of Amplicon Deep Sequencing Underlines Its Utility in Clinical Applications Vera Grossmann, Andreas Roller, Hans-Ulrich Klein, Sandra Weissmann,

Next-Generation Sequencing-Assisted DNA-Based Digital PCR for a Personalized Approach to the Detection and Quantification of Residual Disease in Chronic.

False Positives in Multiplex PCR-Based Next-Generation Sequencing Have Unique Signatures Chad M. McCall, Stacy Mosier, Michele Thiess, Marija Debeljak,

Simple Detection of Telomere Fusions in Pancreatic Cancer, Intraductal Papillary Mucinous Neoplasm, and Pancreatic Cyst Fluid Tatsuo Hata, Marco Dal.

Analytical Validation of the Next-Generation Sequencing Assay for a Nationwide Signal- Finding Clinical Trial Chih-Jian Lih, Robin D. Harrington, David.

Molecular Analysis of Circulating Cell-Free DNA from Lung Cancer Patients in Routine Laboratory Practice Stephan Bartels, Sascha Persing, Britta Hasemeier,

Application of Single-Molecule Amplification and Resequencing Technology for Broad Surveillance of Plasma Mutations in Patients with Advanced Lung Adenocarcinoma

Angela Leo, Andrew M. Walker, Matthew S

Clinical Validation of a Next-Generation Sequencing Genomic Oncology Panel via Cross-Platform Benchmarking against Established Amplicon Sequencing Assays

Plasmid-Based Materials as Multiplex Quality Controls and Calibrators for Clinical Next- Generation Sequencing Assays David J. Sims, Robin D. Harrington,

Application of Single-Molecule Amplification and Resequencing Technology for Broad Surveillance of Plasma Mutations in Patients with Advanced Lung Adenocarcinoma

Assessment of Capture and Amplicon-Based Approaches for the Development of a Targeted Next-Generation Sequencing Pipeline to Personalize Lymphoma Management

Molecular Diagnosis of Autosomal Dominant Polycystic Kidney Disease Using Next- Generation Sequencing Adrian Y. Tan, Alber Michaeel, Genyan Liu, Olivier.

Utilization of Whole-Exome Next-Generation Sequencing Variant Read Frequency for Detection of Lesion-Specific, Somatic Loss of Heterozygosity in a Neurofibromatosis.

Christopher R. Cabanski, Vincent Magrini, Malachi Griffith, Obi L

Donavan T. Cheng, Talia N. Mitchell, Ahmet Zehir, Ronak H

A Comprehensive Strategy for Accurate Mutation Detection of the Highly Homologous PMS2 Jianli Li, Hongzheng Dai, Yanming Feng, Jia Tang, Stella Chen,

Robust Detection of DNA Hypermethylation of ZNF154 as a Pan-Cancer Locus with in Silico Modeling for Blood-Based Diagnostic Development Gennady Margolin,

A Rapid and Sensitive Next-Generation Sequencing Method to Detect RB1 Mutations Improves Care for Retinoblastoma Patients and Their Families Wenhui L.

Rapid Molecular Profiling of Myeloproliferative Neoplasms Using Targeted Exon Resequencing of 86 Genes Involved in JAK-STAT Signaling and Epigenetic Regulation

Certified DNA Reference Materials to Compare HER2 Gene Amplification Measurements Using Next-Generation Sequencing Methods Chih-Jian Lih, Han Si, Biswajit.

Eric Samorodnitsky, Jharna Datta, Benjamin M

Detection of Germline Mutation in Hereditary Breast and/or Ovarian Cancers by Next- Generation Sequencing on a Four-Gene Panel Ava Kwong, Vivian Y. Shin,

Somak Roy, Christopher Coldren, Arivarasan Karunamurthy, Nefize S

High-Throughput and Sensitive Quantification of Circulating Tumor DNA by Microfluidic- Based Multiplex PCR and Next-Generation Sequencing Yinghui Guan,

Catherine E. Cottrell, Hussam Al-Kateb, Andrew J. Bredemeyer, Eric J

ColoSeq Provides Comprehensive Lynch and Polyposis Syndrome Mutational Analysis Using Massively Parallel Sequencing Colin C. Pritchard, Christina Smith,

Validation and Implementation of a Custom Next-Generation Sequencing Clinical Assay for Hematologic Malignancies Michael J. Kluk, R. Coleman Lindsley,

Comprehensive Diagnostic Testing for Stereocilin

Development of a Next-Generation Sequencing Method for BRCA Mutation Screening Maurice Chan, Shen Mo Ji, Zhen Xuan Yeo, Linda Gan, Eric Yap, Yoon Sim.

Molecular Analysis of the Breast Cancer Genes BRCA1 and BRCA2 Using Amplicon- Based Massive Parallel Pyrosequencing Geneviève Michils, Silke Hollants,

Analytical Validation of Clinical Whole-Genome and Transcriptome Sequencing of Patient-Derived Tumors for Reporting Targetable Variants in Cancer Kazimierz.

Detection of Mutations in Myeloid Malignancies through Paired-Sample Analysis of Microdroplet-PCR Deep Sequencing Data Donavan T. Cheng, Janice Cheng,

The c.1364C>A (p.A455E) Mutation in the CFTR Pseudogene Results in an Incorrectly Assigned Carrier Status by a Commonly Used Screening Platform Kristin.

Utility of NIST Whole-Genome Reference Materials for the Technical Validation of a Multigene Next-Generation Sequencing Test Bennett O.V. Shum, Ilya.

A Highly Sensitive Genetic Protocol to Detect NF1 Mutations

Syed Hussain Askree, Lawrence N

Sanger Confirmation Is Required to Achieve Optimal Sensitivity and Specificity in Next- Generation Sequencing Panel Testing Wenbo Mu, Hsiao-Mei Lu, Jefferey.

Larissa V. Furtado, Helmut C. Weigelin, Kojo S. J

A Variant Detection Pipeline for Inherited Cardiomyopathy–Associated Genes Using Next-Generation Sequencing Théo G.M. Oliveira, Miguel Mitne-Neto, Louise.

Genomic Technologies and the New Era of Genomic Medicine

Analytical Validation of the Next-Generation Sequencing Assay for a Nationwide Signal- Finding Clinical Trial Chih-Jian Lih, Robin D. Harrington, David.

A Clinically Validated Diagnostic Second-Generation Sequencing Assay for Detection of Hereditary BRCA1 and BRCA2 Mutations Ian E. Bosdet, T. Roderick.

Avoiding Pitfalls in Molecular Genetic Testing

Evaluation of Second-Generation Sequencing of 19 Dilated Cardiomyopathy Genes for Clinical Applications Sivakumar Gowrisankar, Jordan P. Lerner-Ellis,

Molecular Diagnosis of Mosaic Overgrowth Syndromes Using a Custom-Designed Next- Generation Sequencing Panel Fengqi Chang, Liu Liu, Erica Fang, Guangcheng.

A Pyrosequencing-Based Assay for the Rapid Detection of the 22q11

A Platform for Rapid Detection of Multiple Oncogenic Mutations With Relevance to Targeted Therapy in Non–Small-Cell Lung Cancer Zengliu Su, Dora Dias-Santagata,

Custom Design of a GeXP Multiplexed Assay Used to Assess Expression Profiles of Inflammatory Gene Targets in Normal Colon, Polyp, and Tumor Tissue Janice.

Nathan D. Montgomery, Sara R. Selitsky, Nirali M. Patel, D

MET Exon 14 Alterations and New Resistance Mutations to Tyrosine Kinase Inhibitors: Risk of Inadequate Detection with Current Amplicon-Based NGS Panels

Optimized Allele-Specific Real-Time PCR Assays for the Detection of Common Mutations in KRAS and BRAF Alois H. Lang, Heinz Drexel, Simone Geller-Rhomberg,

Development of a Novel Next-Generation Sequencing Assay for Carrier Screening in Old Order Amish and Mennonite Populations of Pennsylvania Erin L. Crowgey,

Presentation transcript:

Analytical Validation and Application of a Targeted Next-Generation Sequencing Mutation-Detection Assay for Use in Treatment Assignment in the NCI-MPACT Trial Chih-Jian Lih, David J. Sims, Robin D. Harrington, Eric C. Polley, Yingdong Zhao, Michele G. Mehaffey, Thomas D. Forbes, Biswajit Das, William D. Walsh, Vivekananda Datta, Kneshay N. Harper, Courtney H. Bouk, Lawrence V. Rubinstein, Richard M. Simon, Barbara A. Conley, Alice P. Chen, Shivaani Kummar, James H. Doroshow, Paul M. Williams The Journal of Molecular Diagnostics Volume 18, Issue 1, Pages 51-67 (January 2016) DOI: 10.1016/j.jmoldx.2015.07.006 Copyright © 2016 Terms and Conditions

Figure 1 Workflows and turnaround time of the NCI-MPACT assay. Seven steps from receipt of biopsy to report are displayed in arrow-shaped boxes. The estimated turnaround times of each step and of the entire process are indicated at the left and bottom, respectively. aMOI, actionable mutations of interest. The Journal of Molecular Diagnostics 2016 18, 51-67DOI: (10.1016/j.jmoldx.2015.07.006) Copyright © 2016 Terms and Conditions

Figure 2 Distribution of 380 actionable mutations detected validation studies. Distribution of 380 actionable mutations of interest (aMOI) is categorized by the variant type (A), gene (B), gain or loss of function (C), and rules of aMOI selection (D). Numbers or percentages of variant counts are indicated. COSMIC, Catalog of Somatic Mutation in Cancer database21,22; HP, homopolymeric; SNV, single-nucleotide variant. The Journal of Molecular Diagnostics 2016 18, 51-67DOI: (10.1016/j.jmoldx.2015.07.006) Copyright © 2016 Terms and Conditions

Figure 3 Amplicon read depth and detection of challenging variants. A: Box plot of read depth of 383 amplicons in each of 191 samples used in validation study. The outliers are indicated as solid dots and the 450× cutoff is indicated as a dashed line. B: Scatterplot of median amplicon read depth across 191 samples versus amplicon length (primer trimmed). Sixteen amplicons with median read depth <450× (dashed line) in 191 samples are shown as red dots (see amplicon information in Supplemental Table S7). C: Reads mapping to the loci of two variants that were not detected on the NCI-MPACT assay were examined by the Integrated Genome Viewer.54 The deleted or inserted bases are indicated by red arrows. Insets summarizing the loci base count show both that indel variants reside in the mapped reads and that the TS3.2.1 pipeline failed to call the variants. D: Effects of indel gap size and homopolymeric (HP) length on the ability of the NCI-MPACT assay to detect variants. Top panel: Thirty detected (red) and two missed (gray) indel type variants (six indels, 15 indels at HP regions, and 11 large indels) plotted versus gap size. Lower panel: Twenty-four detected (red) and one missed (gray) HP adjacent variants (one large indel, six single nucleotide variants at HP, and 15 indels at HP) plotted versus their HP length. The Journal of Molecular Diagnostics 2016 18, 51-67DOI: (10.1016/j.jmoldx.2015.07.006) Copyright © 2016 Terms and Conditions